λ縻 - ѱ (Ѿȸ ̻) |
08:50-09:00 |
|
|
|
1.Next-generation omics data analysis for cancer research |
09:00-10:30 |
| : ¹ (Ǵ) |
1) Exploring the NCI genomic data commons for cancer research
| ȫ (縯Ǵ) |
2) Whole genome sequencing in precision oncology |
ڼ (GENOME INSIGHT Inc.) |
3) Single-cell combinatorial indexed cytometry sequencing in cancer-immunology research |
Ȳ (UCSF) |
|
|
|
Break |
10:30-10:40 |
|
|
|
2. New drug development and approval in oncology |
10:40-12:10 |
| : (հǴ) |
1) PROTACs as a new therapeutic modality |
º (Ǵ) |
2) Clinical trial design for new anti-cancer drug |
赿 (Ǵ) |
3) Companion diagnostics and the future of oncology clinical trial design |
(հǴ) |
|
|
|
Lunch Break |
12:10-12:50 |
|
|
|
3. Patient-derived and genetically engineered animal models for cancer research |
12:50-14:20 |
| : (Ǵ) |
1) Development of genetically engineered and chemically induced cancer models and their application for therapeutic research |
(DGIST) |
2) Cancer research using patient tissue: Tumorsphere utilization and interpretation of genomic information |
(Ǵ) |
3) Preclinical cancer models for drug development: ImmunoOncological aspect |
̵ (Ǵ) |
|
|
|
Break |
14:20-14:30 |
|
|
|
4. Immunometabolism in cancer immunology |
14:30-16:00 |
| : ϻ () |
1) Metabolic and functional adaptation of regulatory T cells in the tumor microenvironment |
Ӽ (St Jude Childrens Research Hospital) |
2) Glutamine and immune checkpoint in cancer cells |
ڱٱ (Ǵ) |
3) Spatial biology in immune-directed cancer therapeutic landscape: Intercellular communications and metabolic implication |
ȣ (Ǵ) |